Clinical Trial Update: Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a multitarget kinase inhibitor in combination with a PD-1 antibody in patients with advanced thyroid cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• Multitarget kinase inhibitor (unspecified) (multitarget kinase inhibitor)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Fudan University | Conditions: Thyroid Cancer | Phase 2 | Status: COMPLETED